In the replicate phase 3 OBERON and TITANIA trials, add-on tozorakimab 300 mg every 4 weeks significantly reduced annualized moderate or severe chronic obstructive pulmonary disease exacerbation rates...
In 2 phase 3 randomized, placebo-controlled trials of adults and adolescents with nonsegmental vitiligo, once-daily upadacitinib 15 mg significantly improved facial and total-body repigmentation at 48...
The FDA approved the first-in-class targeted therapy based on a clinical trial evaluating overall survival among adults with previously treated metastatic pancreatic adenocarcinoma.
Intismeran autogene plus pembrolizumab met the primary recurrence-free survival and a key secondary distant metastasis-free survival endpoint in the phase 3 INTerpath-001 trial in patients with completely...
In a multicenter dose de-escalation and expansion study of adults with HIV-related DLBCL, ibrutinib plus R-da-EPOCH showed manageable toxicity and clinical activity, with 3-year event-free and overall...
In a phase 3 RCT of children aged 3 to 17 years with achondroplasia, once-daily oral infigratinib significantly increased annualized height velocity vs placebo at 52 weeks.
In 6-year long-term follow-up of adults with severe or moderately severe hemophilia B, single-dose fidanacogene elaparvovec maintained FIX activity and low treated annualized bleeding rates.
